Medically reviewed by Steffini Stalos, DO Hemophilia disease is a rare inherited bleeding disorder. People with this genetic ...

A lack or decrease of clotting factor IX (FIX) causes hemophilia B, also called Christmas disease. Hemophilia B is four times less common than hemophilia A, according to the National Hemophilia ...

Hemophilia B treatment typically involves regular factor IX infusions. The latest research includes two gene therapy drugs that may reduce the need for these infusions. Though research is still ...

Opens in a new tab or window Less than a year after approval, Pfizer said it plans to discontinue its hemophilia B gene therapy fidanacogene elaparvovec (Beqvez) across all global markets ...

Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit that the Swiss pharma ...

Hemophilia B is an X-linked recessive hemorrhagic disorder caused by a deficiency or abnormality of clotting factor IX. Human factor IX is a vitamin-K-dependent multidomain glycoprotein composed ...

Originally developed by Spark Therapeutics, Beqvez was licensed by Pfizer in 2014 and gained U.S. approval last April for people with hemophilia B, the less common form of the genetic bleeding ...

The New York pharma is ending global development and commercialization of Beqvez less than a year after an FDA approval for the gene therapy to treat hemophilia B. The one-time treatment carried a ...

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and commercialization of its hemophilia B gene therapy, Beqvez. In April 2024 ...